Effect of omeprazole on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats

被引:9
作者
Zhou, QY [1 ]
Chan, E [1 ]
机构
[1] Natl Univ Singapore, Dept Pharm, Singapore 117543, Singapore
关键词
warfarin; omeprazole; pharmacokinetics; pharmacodynamics; drug interactions; rats;
D O I
10.1016/j.ejps.2003.09.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effect of the proton pump inhibitor omeprazole on the anticoagulation and the pharmacokinetics of warfarin enantiomers was studied in rats. Omeprazole given intraperitoneally in a daily dose of 0.67 mg/kg over 8 days had no significant effect on the absorption, distribution and the total serum clearance values of the S- and R-enantiomers of warfarin. Omeprazole did not affect the pre-treatment baseline blood coagulation and the in vitro rat serum protein binding of warfarin enantiomers. In vitro study with rat liver microsomes showed that omeprazole had an inhibitory effect on the hydroxylation of warfarin enantiomers. Results obtained from in vivo urinary excretion study revealed that omeprazole inhibited the formation clearance of both S- and R-form oxidative metabolites, but increased that of the overall reductive metabolites, and the renal clearance of S- and R-enantiomers, of warfarin. As a consequence, the total serum clearance values for warfarin enantiomers remained unchanged and the hypoprothrombinaemic response produced by warfarin was not affected. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:439 / 449
页数:11
相关论文
共 45 条
  • [1] ABERNETHY DR, 1991, J PHARMACOL EXP THER, V257, P411
  • [2] OMEPRAZOLE DRUG-INTERACTION STUDIES
    ANDERSSON, T
    [J]. CLINICAL PHARMACOKINETICS, 1991, 21 (03) : 195 - 212
  • [3] SLOW OMEPRAZOLE METABOLIZERS ARE ALSO POOR S-MEPHENYTOIN HYDROXYLATORS
    ANDERSSON, T
    REGARDH, CG
    DAHLPUUSTINEN, ML
    BERTILSSON, L
    [J]. THERAPEUTIC DRUG MONITORING, 1990, 12 (04) : 415 - 416
  • [4] STEREOSPECIFIC FLUORESCENCE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ANALYSIS OF WARFARIN AND ITS METABOLITES IN PLASMA AND URINE
    BANFIELD, C
    ROWLAND, M
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1984, 73 (10) : 1392 - 1396
  • [5] BRECKENRIDGE A, 1974, CLIN PHARMACOL THER, V15, P424
  • [6] STEREOCHEMICAL ASPECTS OF WARFARIN DRUG-INTERACTIONS - USE OF A COMBINED PHARMACOKINETIC-PHARMACODYNAMIC MODEL
    CHAN, E
    MCLACHLAN, A
    OREILLY, R
    ROWLAND, M
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (03) : 286 - 294
  • [7] CHOONARA IA, 1988, BRIT J CLIN PHARMACO, V25, P1
  • [8] OMEPRAZOLE - A PRELIMINARY REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC POTENTIAL IN PEPTIC-ULCER DISEASE AND ZOLLINGER-ELLISON SYNDROME
    CLISSOLD, SP
    CAMPOLIRICHARDS, DM
    [J]. DRUGS, 1986, 32 (01) : 15 - 47
  • [9] BIOCHEMICAL APPLICATIONS OF A QUANTITATIVE HIGH-PRESSURE LIQUID-CHROMATOGRAPHIC ASSAY OF WARFARIN AND ITS METABOLITES
    FASCO, MJ
    PIPER, LJ
    KAMINSKY, LS
    [J]. JOURNAL OF CHROMATOGRAPHY, 1977, 131 (JAN21): : 365 - 373
  • [10] SUBSTITUTED BENZIMIDAZOLES INHIBIT GASTRIC-ACID SECRETION BY BLOCKING (H++K+)ATPASE
    FELLENIUS, E
    BERGLINDH, T
    SACHS, G
    OLBE, L
    ELANDER, B
    SJOSTRAND, SE
    WALLMARK, B
    [J]. NATURE, 1981, 290 (5802) : 159 - 161